PR93151

LONDON, Nov. 18, 2021 /PRNewswire=KYODO JBN/ --

-- Dr. Steffen Wagner appointed as new Chief Executive Officer and Andreas

Stickler as new Chief Financial Officer

ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty

pharmaceutical company with a strategic focus on complex medicines in Europe,

today announced several changes in senior leadership roles as it enters the

next phase of its growth journey.

Photo - https://mma.prnewswire.com/media/1691859/Dr_Steffen_Wagner.jpg

Dr Steffen Wagner is to become the new Chief Executive Officer of ADVANZ

PHARMA, starting early 2022. He succeeds Graeme Duncan, who will step down from

his role and become a special advisor to the Board. Andreas Stickler will join

from Merck Healthcare as the new Chief Financial Officer, succeeding Adeel

Ahmad.

Dr Steffen Wagner is currently a member of the executive management team at

STADA Arzneimittel AG and has been responsible for the company's European

Markets division. Steffen is a medical doctor by training, has previously held

senior roles with Biogen and within the Novartis Group, and worked as a

consultant at McKinsey & Company and Bain & Company. He brings extensive

international pharma experience that will be highly valuable in supporting

ADVANZ PHARMA's continued journey. His predecessor, Graeme Duncan, has been

with ADVANZ PHARMA since 2014 and has played a significant role in building the

Company to date. He will continue working with the Board as a special advisor.

Andreas Stickler will join as the Company's new Chief Financial Officer in

January 2022. Most recently, he has been CFO of Merck Healthcare, part of Merck

KGaA, where he also served as Global Head of M&A and Business Development,

driving major strategic acquisitions. He brings a wealth of global finance,

healthcare and M&A expertise to the team. His predecessor, Adeel Ahmad, has

been with the Company since 2013 and has helped deliver major transformation

projects and built a sustainable business from which to grow.

These two key additions to the executive team of ADVANZ PHARMA are accompanied

by several other senior leadership changes. On November 1, 2021, Susanna

El-Armale joined as Chief Corporate Development Officer, following her prior

role as Chief Corporate Development Officer of Theramex and succeeding former

Chief Corporate Development Officer Guy Clark. Susanna brings broad experience

spanning both M&A and BD activities and will be a central driver of the

Company's active corporate development agenda. In January 2022, Chris Britten

will join Susanna El-Armale's team as Senior Vice President for M&A, following

his role as Head, M&A for Neuraxpharm. On October 11, Anke Niedernberg joined

as Senior Vice President and Head of the Transformation Office. She brings a

broad skillset to the leadership team, having spent time in private equity,

consulting and running major change and growth projects for Sandoz for the last

ten years.

These senior leadership changes build upon ADVANZ PHARMA's successful 2021 and

will help fuel the Company's next phase of growth. In 2021, the Company

delivered continued strong financial performance, succeeded in acquiring

additional strategic assets, commenced the European launch of a generic version

of Lanreotide and bolstered its organic pipeline with further in-licensing

deals. ADVANZ PHARMA continues building towards achieving its corporate vision

of becoming the "partner of choice" for complex specialty and hospital

medicines in Europe.

About ADVANZ PHARMA

ADVANZ PHARMA is headquartered in London and has commercial affiliates in

Europe, North America and Australia, and supply chain, regulatory and

administrative operations in India. Furthermore, ADVANZ PHARMA has an

established global network of commercial partners throughout the rest of the

world. With an agile and experienced team, including direct sales, marketing,

and medical capability across many of Europe's major markets, ADVANZ PHARMA

supplies, innovates and enhances the critical medicines patients depend on,

ensuring continued patient access and improving healthcare outcomes. ADVANZ

PHARMA has a broad expertise in several therapeutic areas with strengths in the

critical care, anti-infectives, endocrinology, cardiovascular and central

nervous system therapeutic areas, along with direct sales access in Europe,

making it an attractive partner when commercialising complex medicines,

especially in the hospital channel. To find out more, please visit our website:

https://www.advanzpharma.com.

Press contacts: Meral Nugent, Head of Communications, Tel: +44 7557 49 60 35,

E-mail: meral.nugent@advanzpharma.com

SOURCE: ADVANZ PHARMA Corp.